Company intelligence / Profile preview

Equilibre Biopharmaceuticals

New York, New York, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

EQU-001 demonstrated positive Phase 2 results as an adjunctive therapy for focal seizures in adults with epilepsy, showing safety and tolerability at all tested doses through 60 mg QD with no treatment-related Serious Adverse Effects. A dose-dependent decrease in per 28-day focal seizure frequency was observed with a 35.7% median reduction over placebo in the 60 mg treatment arm[6].

Therapeutic areas: Neurology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

equ-001

Beyond the preview

Go deeper on Equilibre Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Equilibre Biopharmaceuticals.

Explore the full profile